Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2009 November 2; 119(11): 3226–3235.
Published online 2009 October 1. doi:  10.1172/JCI38374
PMCID: PMC2769186

Adoptive immunotherapy with liver allograft–derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice


After liver transplantation in HCV-infected patients, the virus load inevitably exceeds pre-transplantation levels. This phenomenon reflects suppression of the host-effector immune responses that control HCV replication by the immunosuppressive drugs used to prevent rejection of the transplanted liver. Here, we describe an adoptive immunotherapy approach, using lymphocytes extracted from liver allograft perfusate (termed herein liver allograft–derived lymphocytes), which includes an abundance of NK/NKT cells that mounted an anti-HCV response in HCV-infected liver transplantation recipients, despite the immunosuppressive environment. This therapy involved intravenously injecting patients 3 days after liver transplantation with liver allograft–derived lymphocytes treated with IL-2 and the CD3-specific mAb OKT3. During the first month after liver transplantation, the HCV RNA titers in the sera of recipients who received immunotherapy were markedly lower than those in the sera of recipients who did not receive immunotherapy. We further explored these observations in human hepatocyte–chimeric mice, in which mouse hepatocytes were replaced by human hepatocytes. These mice unfailingly developed HCV infections after inoculation with HCV-infected human serum. However, injection of human liver–derived lymphocytes treated with IL-2/OKT3 completely prevented HCV infection. Furthermore, an in vitro study using genomic HCV replicon–containing hepatic cells revealed that IFN-γ–secreting cells played a pivotal role in such anti-HCV responses. Thus, our study presents what we believe to be a novel paradigm for the inhibition of HCV replication in HCV-infected liver transplantation recipients.


Liver failure and hepatocellular carcinoma (HCC) due to chronic hepatitis C infection are the most common indications for liver transplantation (LT), and the incidences of both have been projected to increase further in the future. Recurrent HCV infection of the allograft is universal, occurs immediately after LT, and is associated with accelerated progression to cirrhosis, graft loss, and death (1, 2). This reflects the suppression of those host-effector immune responses that usually control HCV replication, suggesting that the immunosuppressive environment may play a major role in the rapid progression of recurrent HCV infection after LT (3, 4). Further, the immunosuppressive condition described above is considered to increase the incidence of cancer recurrence after LT in HCC patients. We recently proposed the novel strategy of adjuvant immunotherapy for preventing the recurrence of HCC after LT; this immunotherapy involves intravenously injecting LT recipients with activated liver allograft–derived NK cells (5, 6). Since the immunosuppressive regimen currently used after LT reduces the adaptive immune components but effectively maintains the innate components of cellular immunity (79), the augmentation of the NK cell response, which is thought to play a pivotal role in innate immunity, may be a promising immunotherapeutic approach (6). We confirmed that the IL-2/anti-CD3 mAb–treated (IL-2/OKT3–treated) liver allograft–derived NK cells expressed a significantly high level of the tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), which is a critical molecule for tumor cell killing. Further, these cells showed high cytotoxicity against HCC cells, with no such effect on normal cells (5). After obtaining approval from the ethical committee of our institute, we successfully administered adoptive immunotherapy with IL-2/OKT3–treated liver lymphocytes to liver cirrhosis patients with HCC in a phase I trial. Although the long-term benefits of this approach with regard to the control of HCC recurrence after LT remain to be elucidated, this trial provided a unique opportunity to study whether the adoptive administration of IL-2/OKT3–treated liver lymphocytes could also mount an anti-HCV response in HCV-infected LT recipients.

Previous studies have highlighted the important roles of innate lymphocytes in developing immunity against hepatotropic viruses, including HCV (10, 11). In this regard, it is known that patients with chronic HCV infection show diminished NK and NKT cell responses (1214). In the case of an LT, it has recently been reported that the host CD56+ innate lymphocyte population, consisting of NK and NKT cells, is appreciably associated with the severity of HCV recurrence after LT (15). These insights into the immunopathogenesis of HCV recurrence indicate that the innate immune components mentioned above are potential targets for therapeutic manipulation. In this study, we have demonstrated for the first time to our knowledge that adoptive immunotherapy with IL-2/OKT3–treated liver lymphocytes, including abundant NK and NKT cells, shows anti-HCV activity after LT, even in an immunosuppressive environment.


Adoptive transfer of IL-2/OKT3–treated liver lymphocytes.

The human liver contains a significant number of resident lymphocytes. These cells include abundant CD56+ NK and NKT cells, many of which differ phenotypically and functionally from the circulating cells (14, 16). In our previous study, we performed ex vivo perfusion of the liver through the portal vein, which was necessary in order to flush blood from the liver graft before implantation. Liver-resident lymphocytes were then extracted from the perfusates (number of lymphocytes extracted from normal liver perfusates, 0.5 ± 0.1 cells per gram of liver weight; n = 14) (5). Proportions of CD56+CD3 NK cells and CD56+CD3+ NKT cells among the lymphocytes extracted from the liver perfusates (NK cells, 46.4% ± 4.2%; NKT cells, 17.2% ± 2.3%; n = 14) were significantly (P < 0.05) higher than those among the lymphocytes derived from the peripheral blood of the same donors (NK cells, 21.9% ± 3.7%; NKT cells, 3.8% ± 0.9%; n = 14). Extensive preclinical studies have shown that liver allograft–derived resident NK cells mediate remarkably higher cytotoxic activity against HCC cells than do peripheral blood NK cells (5). On this basis, we undertook a clinical trial of adjuvant immunotherapy with IL-2/OKT3–treated liver lymphocytes for preventing the recurrence of HCC after LT in 14 recipients with HCC (Figure (Figure11 and Tables Tables11 and and2).2). The therapy involved administering a single intravenous injection of IL-2/OKT3–treated liver lymphocytes to recipients 3 days after LT (2–5 × 108 cells injected per subject). In order to prevent graft-versus-host disease (GVHD), i.e., to inactivate CD3+ alloreactive T cells, we added an anti-CD3 mAb, OKT3, to the culture medium a day before the inoculation. During the follow-up period (mean, 23.4 months; range, 10.7–32.9 months), neither any remarkable adverse effects nor rejection episodes occurred. All 14 subjects who received the immunotherapy were alive without recurrence of HCC after LT (including 5 patients with HCC exceeding the Milan criteria; ref. 17). At our institute, the survival rate and recurrence rate of historical control patients with HCC exceeding the Milan criteria were 78% (30 of 37) and 10.8% (4 of 37), respectively. The lymphocytes in the peripheral blood of LT recipients who received immunotherapy in the early postoperative period showed significantly enhanced cytotoxicity against an HCC cell line (HepG2) as compared with those in the peripheral blood of LT recipients who did not receive the therapy in the same period (Figure (Figure2A).2A). Although the gross proportions of NK/NKT cells in the peripheral blood of patients treated with immunotherapy did not differ from those in the peripheral blood of untreated patients, the proportions of TRAIL+ NK cells significantly increased after immunotherapy in the peripheral blood of the former patients. This increase in the TRAIL+ NK cells in the peripheral blood lymphocytes was not observed in untreated patients (Figure (Figure2B).2B). Furthermore, there was a significant correlation between the frequency of TRAIL+ NK cells in the peripheral blood lymphocytes and the NK cytolytic activity of the peripheral blood lymphocytes at 7 days after LT (Spearman rank-order correlation coefficient = 0.54, P = 0.01; Figure Figure2C),2C), indicating the anti-HCC effect of adoptively injected TRAIL+ NK cells. It would be pertinent to conduct additional clinical trials of this immunotherapy for preventing HCC recurrence after LT.

Figure 1
Schematic outline of adoptive immuno­therapy with lymphocytes extracted from liver allograft perfusate.
Figure 2
Adoptive immunotherapy with IL-2/OKT3–treated liver lymphocytes promoted the cytotoxic activity and TRAIL expression of NK cells in LT recipients.
Table 1
Recipient and tumor characteristics
Table 2
Donor and graft characteristics

Anti-HCV activity after adoptive immunotherapy.

Of the 14 LT recipients who received the immunotherapy, 7 had chronic HCV infection. During the period of this trial, 5 other HCV-infected LT recipients who did not agree to receive immunotherapy served as controls; the background of the controls, including HCV genotype, age, and immunosuppressive therapy, was similar to that of the immunotherapy recipients (Table (Table3).3). It has been reported that HCV RNA concentrations sharply decrease a day after LT and increase rapidly thereafter (3). In some of the patients, who did not receive the immunotherapy, HCV RNA titers remained lower than that of the pretransplant titer 1 week after LT, suggesting the individual variation of increasing tempo. However, in almost all patients, HCV RNA titers exceeded the pretransplantation levels by 2 weeks after LT. Notably, HCV infection disappeared in 2 LT recipients after the immunotherapy, but this was not observed in the case of any HCV-infected LT recipients who did not receive the therapy. In one of these patients (who had the lowest HCV RNA levels before LT), HCV RNA has not been detected to date (20 months after LT), even with a qualitative assay. In the other patient, HCV RNA became detectable at 2 months after LT. On the other hand, the 2 patients with the highest HCV viral loads did not respond at all to the immunotherapy. Thus, the effects of immunotherapy were dependent on the HCV virus load before LT, probably because of the proportion of effectors and targets. All patients with HCV viremia are currently being treated with pegylated IFN-α2b and ribavirin. Nevertheless, during the first month after LT, the HCV RNA titers in the sera of LT recipients who received the immunotherapy were statistically lower than those in the sera of LT recipients who did not receive the therapy (P < 0.05) (Figure (Figure3).3). Among the LT recipients who received the immunotherapy, at 2 weeks after LT, HCV RNA remained undetectable in 4 patients (responders), whereas it was detectable in the other 3 patients (nonresponders). The serum ALT levels did not differ between the responders and nonresponders (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI38374DS1), suggesting that the immunotherapy did not inhibit HCV RNA by injuring HCV-infected hepatocytes.

Figure 3
Serial measurement of the HCV RNA titers of LT recipients after LT.
Table 3
Characteristics of HCV-infected LT recipients that received and did not receive immunotherapy

In vitro evidence to prove the anti-HCV activity of IL-2/OKT3–treated liver lymphocytes by using HCV replicon–containing hepatic cells.

The liver allograft–derived lymphocytes were cultured in complete medium with and without IL-2 for 3 days. This was followed by adding OKT3 to the culture medium 1 day before coculturing the lymphocytes with HCV replicon–containing hepatic cells in a transwell system, at an indicated time. While the freshly isolated liver allograft–derived lymphocytes inhibited HCV replication in the HCV replicon–containing hepatic cells to some extent, the cultivation of these lymphocytes with IL-2/OKT3 markedly promoted anti-HCV activity. Absence of exposure to either IL-2 or OKT3 resulted in reduced anti-HCV activity of the lymphocytes (OKT3 had a more profound influence than IL-2) (Figure (Figure4A).4A). When the lymphocytes were treated with IL-2 alone, the CD56+ fraction, including NK and NKT cells, that had been isolated by magnetic cell sorting inhibited HCV replication more strongly than the CD56 fraction; further, the CD3CD56+ NK cell and CD3+CD56+ NKT cell subfractions showed equivalent anti-HCV activity (Figure (Figure4,4, B and C). On the other hand, when the lymphocytes were treated with both IL-2 and OKT3, the CD56+ and CD56 fractions showed similar levels of anti-HCV activity (Figure (Figure4B).4B). After the treatment with IL-2 and OKT3, IFN-γ was the predominant cytokine in the culture supernatant of the lymphocytes (Figure (Figure5A),5A), and intracellular IFN-γ expression was induced in the CD3CD56+ NK, CD3+CD56+ NKT, and CD3+CD56 T cells (Figure (Figure5B).5B). There was no difference between the proportions of TRAIL+ and TRAIL CD3CD56+ NK cells producing IFN-γ (Supplemental Figure 2). Adding mAb against IFN-γ to the coculture of lymphocytes with HCV replicon cells markedly weakened the anti-HCV effects. The incomplete restoration of the anti-HCV effect by anti–IFN-γ treatment suggests the possibility that other inflammatory cytokines may also be responsible for the anti-HCV effect, although we have not defined them at present (Figure (Figure5C).5C). Thus, the vigorous anti-HCV activity of IL-2/OKT3–treated liver lymphocytes was dependent, at least in part, on their IFN-γ–secreting activity.

Figure 4
The cultivation of liver lymphocytes with IL-2/OKT3 markedly promoted anti-HCV activity.
Figure 5
Anti-HCV activity of IL-2/OKT3–treated liver lymphocytes was dependent on their IFN-γ secretion ability.

IFN-γ–secreting activity in LT recipients after adoptive immunotherapy.

At 14 days after LT, the number of IFN-γ–secreting cells in the peripheral blood of LT recipients who received adoptive immunotherapy was significantly higher than that in the peripheral blood of LT recipients who did not receive immunotherapy during the trial period (Figure (Figure6).6). This result was consistent with the results of the in vitro studies showing the crucial role of IFN-γ produced in IL-2/OKT3–treated liver lymphocytes.

Figure 6
Adoptive immunotherapy with IL-2/OKT3–treated liver lymphocytes induced the production of IFN-γ in the LT recipients.

In vivo evidence to prove the anti-HCV activity of adoptive immunotherapy by using HCV-infected human hepatocyte–chimeric mice.

HCV-infected mice have previously been developed by inoculating HCV-infected human serum into chimeric urokinase-type plasminogen activator–SCID (uPA-SCID) mice with engrafted human hepatocytes (18). This HCV-infected mouse model has been reported to be useful for evaluating anti-HCV drugs such as IFN-α and anti-NS3 protease (19). We also generated a human hepatocyte–chimeric mouse model, in which mouse hepatocytes were almost completely replaced by human hepatocytes (20). These mice consistently developed long-term HCV infections, showing high viral titers after inoculation with HCV genotype 1b–infected human serum (50 μl/mouse) (Supplemental Figure 3). Intraperitoneal injection of IL-2/OKT3–treated liver lymphocytes (20 × 106 cells/mouse), at 2 weeks after inoculation with the infected serum, consistently prevented the development of HCV infection in the human hepatocyte–chimeric mice (Figure (Figure7A).7A). Such anti-HCV effects were countered by anti–IFN-γ neutralizing antibodies in some chimeric mice, suggesting the potential role played by IFN-γ in the anti-HCV effects of the immunotherapy. The administration of recombinant human IFN-γ markedly and consistently prevented the development of HCV infection in the human hepatocyte–chimeric mice. Once the HCV RNA became undetectable in the sera of chimeric mice receiving either IL-2/OKT3–treated liver lymphocytes or recombinant IFN-γ, it could not be detected again. The constant levels of human serum albumin in the chimeric mice indicated that neither the immunotherapy nor recombinant IFN-γ administration had significant adverse effects on human hepatocytes in those mice (Figure (Figure7B).7B). Once HCV infection had developed in the human hepatocyte–chimeric mice, who showed high titers of HCV RNA in their sera (over 103 copies/ml) 4 weeks after the inoculation of HCV-infected serum, the preventive effects of the adoptive immunotherapy or recombinant IFN-γ on HCV infection were no longer observed (Figure (Figure7C). 7C).

Figure 7
Adoptive immunotherapy with IL-2/OKT3–treated liver lymphocytes prevented HCV infection in human hepatocyte–chimeric mice.


The consequences of recurrent hepatitis C on the survival of graft and LT recipients can only be avoided by the development of safe and effective antiviral strategies that can not only prevent initial graft infection but also eradicate established hepatitis C recurrence (3, 4). With regard to initial graft infection, the circulating virions infect the liver graft immediately after LT. HCV RNA concentrations usually increase a few days after LT, reflecting active HCV replication in the liver graft. In general, in such an early phase of a viral infection, the first line of host defense may be effective in removing the virus; however, recent reports have indicated that HCV effectively escapes the innate immune system comprising NK and NKT cells, resulting in persistent infection (21, 22). It has been reported that cross-linking of CD81 on NK cells by the major envelope protein of HCV, HCV-E2, blocks NK cell activation, IFN-γ production, cytotoxic granule release, and proliferation (21). Engagement of CD81 on NK cells blocks tyrosine phosphorylation through a mechanism that is distinct from the negative signaling pathways associated with NK cell inhibitory receptors for major histocompatibility complex class I molecules (22). These facts prove that HCV-E2–mediated inhibition of NK cells is an efficient HCV evasion strategy, which involves targeting the early antiviral activities of NK cells and allowing the virus to establish itself as a chronic infection.

We have explored whether CD81 cross-linking–induced inhibitory effects occur even in IL-2–stimulated NK cells. CD81 cross-linking by a mAb specific for CD81 inhibited antitumor cytotoxicity and anti-HCV activity mediated by resting NK cells, but this manipulation did not alter both these activities of IL-2–stimulated NK cells (Supplemental Figure 4). This indicated that exposure to IL-2 before CD81 cross-linking abrogates subsequent inhibitory signals in the NK cells. This would be one mechanism whereby the adoptive immunotherapy with IL-2/OKT3–treated liver lymphocytes inhibited HCV replication at the early phase of infection after LT.

Although the role of NK cells in controlling HCV infection and replication has not been completely elucidated, a recent report has indicated that NK cells do not exert a direct cytolytic effect on the HCV replicon–containing hepatic cells but release IFN-γ, suppressing HCV RNA expression (11). The role of IFN-γ in the expression of NK cell–mediated anti-HCV activity has been proved by the observation that NK cell–conditioned media have an enhanced expression of signal transducer and activator of transcription 1, a nuclear factor that is essential in IFN-γ–mediated antiviral pathways. It has also been reported that hepatocytes cultured in NK cell–conditioned media express higher levels of IFN-α/β, IFN regulatory factor 3, and IFN regulatory factor 7, confirming that NK cells play a key role in suppressing HCV infection of and replication in human hepatocytes in an IFN-dependent manner (23). Similar to recent reports, in the present study, we demonstrated that the NK cells among the IL-2/OKT3–treated liver lymphocytes released soluble factors, predominantly IFN-γ, thus suppressing HCV replication (Figures (Figures557).

In addition to NK cells, NKT cells are thought to be involved in eliciting innate responses against infection; however, the role of NKT cells in controlling HCV infection/replication remains unclear. One report has indicated that the number of NKT cells in patients with chronic HCV infection does not differ from that in healthy donors; however, activated NKT cells in HCV-infected patients produce higher levels of IL-13 — but comparable levels of IFN-γ — than those in healthy subjects, showing that NKT cells are biased toward T-helper 2-type responses in chronic HCV infection (24). Another recent report has shown that the sustained response of patients with chronic hepatitis C to treatment with IFN-α and ribavirin is closely associated with increased dynamism of NK and NKT cells in the liver, implicating an NKT cell–mediated mechanism in anti-HCV activity (25). Here, we have described that NKT as well as NK cells in the IL-2/OKT3–treated liver lymphocytes could play a vital role in controlling HCV replication in hepatic cells via an IFN-γ–associated mechanism (Figures (Figures55 and and6). 6).

Therefore, in the early phase of HCV reinfection after LT, the effects of IFN-γ secretion from adoptively injected liver lymphocytes may include inhibition of HCV virion production, which is probably caused by suppression of viral RNA and protein synthesis without immune lysis of intact hepatic cells. This IFN-γ secretion from both CD3+CD56+ NKT cells and CD3+ T cells was markedly upregulated after treatment with OKT3, which was originally used to prevent GVHD (Figure (Figure5B).5B). This is possibly because of the potent mitogenic activity of OKT3 that induces the activation of CD3+CD56+ NKT cells and CD3+ T cells. However, the administration of OKT3-coated cells in vivo results in the opsonization and subsequent trapping and/or lympholysis of cells by the reticuloendothelial system (2628). Thus, GVHD is prevented in LT recipients treated with adoptive immunotherapy.

Our finding that the IL-2/OKT3–treated liver lymphocytes controlled HCV replication via an IFN-γ–associated mechanism can lead to the clinical application of recombinant IFN-γ for anti-HCV treatment. However, a clinically applicable dose of recombinant IFN-γ could not induce significant inhibitory effects on HCV viremia in the previous study (29). Based on the accumulation of adoptively injected IL-2/OKT3–treated liver lymphocytes in the liver of human hepatocyte–chimeric mice (data not shown), the immunotherapy with the liver lymphocytes would provide sufficient IFN-γ to the HCV-infected site.

It has been recently reported that HCV-specific CD8+ T cells exert strong antiviral effects by both cytopathic and IFN-γ–mediated noncytopathic effector functions (30). However, in patients with chronic HCV infection, dysfunction and functional restoration of HCV-specific CD8+ T cell responses have been reported (31). Since HCV-specific CD8+ T cell defects may be important in persistent HCV infections, correcting these defects is considered to our knowledge to be a novel approach to treat HCV infection. Further studies are required to investigate whether activation of NK or NKT cells functionally restores HCV-specific CD8+ T cells.

In conclusion, adoptive immunotherapy using IL-2/OKT3–treated liver lymphocytes containing abundant NK and NKT cells could mount remarkable anti-HCV responses in HCV-infected LT recipients, although its effects were incomplete or transient. Treatment-related improvements, such as defining the best schedule and frequency of cell inoculation and developing more potent effectors, could improve clinical benefits.



All the human liver samples were collected at Hiroshima University Hospital. Tissue specimens were collected after approval from the Institutional Review Board of Hiroshima University and after written informed consent was obtained from the patients. The use of immunotherapy with IL-2/OKT3–treated liver lymphocytes was approved by the Clinical Institutional Ethical Review Board of Hiroshima University. Written informed consent was obtained from all of the patients. This approach was successfully used in 14 cirrhotic patients with HCC undergoing clinical LT (Tables (Tables11 and and2).2). Of these 14 patients, 7 had chronic HCV infection. Five other LT recipients with chronic HCV infection did not agree to receive this immunotherapy during the trial period. HCV RNA was qualitatively detected in the sera of these patients by a standardized qualitative RT-PCR assay (Amplicor HCV monitor, version 2.0; Roche Diagnostics) every week during the first month after LT.

Isolation of lymphocytes from liver allograft perfusate.

Donor hepatectomy and the transplantation procedure were performed as described previously (32). After hepatectomy, ex vivo perfusion of the liver allograft was performed through the portal vein. Liver allograft–derived lymphocytes were isolated by gradient centrifugation with Ficoll-Paque (GE Healthcare Bio-Sciences AB).

Adoptive transfer of IL-2/OKT3–treated liver lymphocytes.

Liver lymphocytes were cultured with human recombinant IL-2 (100 Japanese reference units/ml [JRU/ml]; Takeda) in complete medium at 37°C in a 5% CO2 incubator for 3 days. One day before the infusion, 1 μg/ml of OKT3 (Janssen-Kyowa) was added in order to opsonize the CD3+ fraction. On the day of infusion, the cells were washed twice with 0.9% sodium chloride and resuspended with 5% human serum albumin in 0.9% sodium chloride for injection (Figure (Figure1).1). The viability of the cells was assessed by the dye-exclusion test, and the cells were checked twice for possible contamination by bacteria, fungi, and endotoxins.

Cytotoxicity assay.

A 51Cr-release assay was done as previously described (5), using HepG2 tumor cells (Japanese Cancer Research Resources Bank) as targets. Briefly, 51Cr-labeled target tumor cells were added for 4 hours at 37°C to effector cells in round-bottomed 96-well microtiter plates (BD Biosciences — Discovery Labware). The percentage of specific 51Cr release was calculated as follows: % cytotoxicity = [(cpm of experimental release – cpm of spontaneous release)/(cpm of maximum release – cpm of spontaneous release)] × 100. All the assays were performed in triplicate.

Flow cytometry.

Flow cytometric analyses were performed using a FACSCalibur dual-laser cytometer (BD Biosciences). The following mAbs were used for the surface staining of the lymphocytes: FITC-conjugated anti-CD3 mAb (clone HIT3a; BD Biosciences — Pharmingen); PE-conjugated anti-CD56 mAb (clone B159; BD Biosciences — Pharmingen); and biotinylated anti-TRAIL (biotin-conjugated anti-TRAIL) mAb (clone RIK-2; eBioscience). The biotinylated mAb was visualized using APC-streptavidin (BD Biosciences — Pharmingen). Dead cells identified by light scatter and propidium iodide staining were excluded from the analysis. IFN-γ production in the lymphocytes was measured by a combination of cell surface and cytoplasmic mAb staining and subsequent flow cytometric analysis, as described previously (33).

Isolation of CD56+ and CD56 fractions and that of NK and NKT cells.

Liver allograft–derived lymphocytes were separated into a CD56+ fraction — including NK and NKT cells — and a CD56 fraction by using auto MACS (Miltenyi Biotec) with anti-human CD56 microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. The NK and NKT cells were also isolated by magnetic cell sorting, using the human NK cell isolation kit or human CD3+CD56+ NKT cell isolation kit (Miltenyi Biotec). The purity of the isolated fractions was assessed by flow cytometric analysis, and only the fractions with purities greater than 90% were used for functional studies.

Coculture with HCV replicon–containing hepatic cells.

An HCV subgenomic replicon plasmid, pRep-Feo, was derived from pRep-Neo (originally, pHCVIbneo-delS; ref. 34). The pRep-Feo carries a fusion gene comprising firefly luciferase (Fluc) and neomycin phosphotransferase, as described elsewhere (35, 36). After culture in the presence of G418 (Invitrogen), pRep-Feo cell lines stably expressing the replicons were established. For coculture experiments, transwell tissue culture plates (pore size, 1 μm; Costar) were used. HCV replicon–containing hepatic cells (105 cells) were incubated in the lower compartment with different numbers of lymphocytes in the upper compartment. The hepatic cells in the lower compartments were collected 48 hours after coculture for the luciferase assay. Luciferase activities were measured with a luminometer (Lumat LB9501; Promega), using the Bright-Glo Luciferase Assay System (Promega).

Cytometric bead array.

Cytokine (IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-10) levels in the coculture assay supernatants were measured with the FACSCalibur dual-laser cytometer (BD Biosciences), using a BD Human Th1/Th2 Cytokine Cytometric Bead Array (CBA) Kit according to the manufacturer’s instructions.

Generation of human hepatocyte–chimeric mice.

Generation of the uPA+/+SCID+/+ mice and transplantation of human hepatocytes were performed as described recently by our group (20, 37). Mouse serum concentrations of human serum albumin correlated with the repopulation index (20), and these were measured as described previously (37).

In vivo studies using human hepatocyte–chimeric mice.

Human hepatocyte–chimeric mice were intravenously injected with 50 μl of the human serum samples positive for HCV genotype 1b. The serum HCV RNA titer in human hepatocyte–chimeric mice was detected by nested PCR, as previously described (38, 39). All animal protocols described in this study were performed in accordance with the guidelines and with approval of the Ethics Review Committee of Animal Experimentation of the Graduate School of Biomedical Sciences, Hiroshima University. Either 2 or 4 weeks after injecting the infected serum, the mice were intraperitoneally inoculated with IL-2/OKT3–treated liver lymphocytes (20 × 106 cells/mouse) for adoptive immunotherapy. When indicated, anti-human IFN-γ mAb (R&D Systems) (1.5 mg/mouse) was injected intraperitoneally 1 day before the immunotherapy. In a separate experiment, intraperitoneal injection of recombinant human IFN-γ (Imunomax-γ; Shionogi & Co. Ltd.) was commenced at either 2 or 4 weeks after injecting the infected serum. IFN-γ was administered as follows: 1 × 105 IU on the first day and thereafter 2 × 104 IU/day for 13 days.


Data are presented as mean ± SEM. The statistical differences of the results were analyzed by 2-tailed, paired Student’s t test, Mann-Whitney U test, and Mann-Whitney U test with Bonferroni correction after the Kruskal-Wallis H test, using the Stat View program. P values of 0.05 or less were considered statistically significant.

Supplementary Material

Supplemental data:


This work was supported in part by a Grant-in-Aid for Exploratory Research (19659323) from the Japan Society for the Promotion of Science. We thank Kentaro Ide, Toshimitsu Irei, Hiroyuki Tahara, Masataka Banshodani, Nabin Basnet, Hirofumi Tazawa, and Keiko Kajitani for their advice and encouragement and Yuko Ishida for expert technical assistance.


Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 119:3226–3235 (2009). doi:10.1172/JCI38374.


1. Petrovic L.M. Early recurrence of hepatitis C virus infection after liver transplantation. Liver Transpl. 2006;12:S32–S37. doi: 10.1002/lt.20942. [PubMed] [Cross Ref]
2. Brown R.S. Hepatitis C and liver transplantation. Nature. 2005;436:973–978. doi: 10.1038/nature04083. [PubMed] [Cross Ref]
3. Garcia-Retortillo M., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–687. doi: 10.1053/jhep.2002.31773. [PubMed] [Cross Ref]
4. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8:S14–S18. doi: 10.1053/jlts.2002.35781. [PubMed] [Cross Ref]
5. Ishiyama K., et al. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology. 2006;43:362–372. doi: 10.1002/hep.21035. [PubMed] [Cross Ref]
6. Ohira M., et al. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation. 2006;82:1712–1719. doi: 10.1097/ [PubMed] [Cross Ref]
7. Miller J.S., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–3057. doi: 10.1182/blood-2004-07-2974. [PubMed] [Cross Ref]
8. Hirata M., et al. Increase in natural killer cell activity following living-related liver transplantation. Transpl. Int. 1998;11(Suppl. 1):S185–S188. [PubMed]
9. Harada N., et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J. Immunol. 2004;173:6635–6644. [PubMed]
10. Golden-Mason L., Rosen H.R. Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl. 2006;12:363–372. doi: 10.1002/lt.20708. [PubMed] [Cross Ref]
11. Li Y., et al. Natural killer cells inhibit hepatitis C virus expression. J. Leukoc. Biol. 2004;76:1171–1179. doi: 10.1189/jlb.0604372. [PubMed] [Cross Ref]
12. Deignan T., et al. Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. J. Hepatol. 2002;37:101–108. doi: 10.1016/S0168-8278(02)00072-7. [PubMed] [Cross Ref]
13. Durante-Mangoni E., et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J. Immunol. 2004;173:2159–2166. [PubMed]
14. Kawarabayashi N., et al. Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology. 2000;32:962–969. doi: 10.1053/jhep.2000.19362. [PubMed] [Cross Ref]
15. Rosen H.R., et al. Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl. 2008;14:31–40. doi: 10.1002/lt.21265. [PubMed] [Cross Ref]
16. Doherty D.G., et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J. Immunol. 1999;163:2314–2321. [PubMed]
17. Mazzaferro V., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996;334:693–699. doi: 10.1056/NEJM199603143341104. [PubMed] [Cross Ref]
18. Mercer D.F., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 2001;7:927–933. doi: 10.1038/90968. [PubMed] [Cross Ref]
19. Kneteman N.M., et al. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology. 2006;43:1346–1353. doi: 10.1002/hep.21209. [PubMed] [Cross Ref]
20. Tateno C., et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 2004;165:901–912. [PubMed]
21. Tseng C.T., Klimpel G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 2002;195:43–49. doi: 10.1084/jem.20020636. [PMC free article] [PubMed] [Cross Ref]
22. Crotta S., et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 2002;195:35–41. doi: 10.1084/jem.20011124. [PMC free article] [PubMed] [Cross Ref]
23. Wang S.H., et al. Natural killer cells suppress full cycle HCV infection of human hepatocytes. . J. Viral Hepat. 2008;15:855–864. doi: 10.1111/j.1365-2893.2008.01014.x. [PMC free article] [PubMed] [Cross Ref]
24. Kanto T., Hayashi N. Innate immunity in hepatitis C virus infection: Interplay among dendritic cells, natural killer cells and natural killer T cells. Hepatol. Res. 2007;37(Suppl. 3):S319–S326. [PubMed]
25. Yamagiwa S., et al. Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol. Res. 2008;38:664–672. doi: 10.1111/j.1872-034X.2008.00317.x. [PubMed] [Cross Ref]
26. Van Wauwe J.P., De Mey J.R., Goossens J.G. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. . J. Immunol. 1980;124:2708–2713. [PubMed]
27. Chang T.W., Kung P.C., Gingras S.P., Goldstein G. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? Proc. Natl. Acad. Sci. U. S. A. 1981;78:1805–1808. doi: 10.1073/pnas.78.3.1805. [PubMed] [Cross Ref]
28. Chatenoud L., et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation. 1990;49:697–702. [PubMed]
29. Soza A., et al. Pilot study of interferon gamma for chronic hepatitis C. J. Hepatol. 2005;43:67–71. doi: 10.1016/j.jhep.2005.02.023. [PubMed] [Cross Ref]
30. Jo J., et al. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology. 2009;136:1391–1401. doi: 10.1053/j.gastro.2008.12.034. [PubMed] [Cross Ref]
31. Penna A., et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology. 2007;45:588–601. doi: 10.1002/hep.21541. [PubMed] [Cross Ref]
32. Ohdan H., et al. Intraoperative near-infrared spectroscopy for evaluating hepatic venous outflow in living-donor right lobe liver. Transplantation. 2003;76:791–797. doi: 10.1097/01.TP.0000074603.36553.BD. [PubMed] [Cross Ref]
33. Tanaka Y., Ohdan H., Onoe T., Asahara T. Multiparameter flow cytometric approach for simultaneous evaluation of proliferation and cytokine-secreting activity in T cells responding to allo-stimulation. Immunol. Invest. 2004;33:309–324. doi: 10.1081/IMM-120038079. [PubMed] [Cross Ref]
34. Guo J.T., Bichko V.V., Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 2001;75:8516–8523. doi: 10.1128/JVI.75.18.8516-8523.2001. [PMC free article] [PubMed] [Cross Ref]
35. Tanabe Y., et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha. J. Infect. Dis. 2004;189:1129–1139. doi: 10.1086/382595. [PubMed] [Cross Ref]
36. Yokota T., et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003;4:602–608. doi: 10.1038/sj.embor.embor840. [PubMed] [Cross Ref]
37. Tsuge M., et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology. 2005;42:1046–1054. doi: 10.1002/hep.20892. [PubMed] [Cross Ref]
38. Hiraga N., et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett. 2007;581:1983–1987. doi: 10.1016/j.febslet.2007.04.021. [PubMed] [Cross Ref]
39. Kimura T., et al. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. J. Gen. Virol. 2008;89:2108–2113. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation